Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: OTC US
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

OphthaliX Inc

+ Add to Watchlist

OPLI:US

1.0500 USD 0.3500 50.00%

As of 20:10:04 ET on 04/21/2015.

Snapshot for OphthaliX Inc (OPLI)

Open: 1.0500 Day's Range: 1.0500 - 1.0500 Volume: 100
Previous Close: 0.7000 52wk Range: 0.5000 - 1.7500 1-Yr Rtn: -

Stock Chart for OPLI

No chart data available.
  • OPLI:US 1.0500
  • 1D
  • 1M
  • 1Y
0.7000
Interactive OPLI Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for OPLI

Current P/E Ratio (ttm) -
Estimated P/E(-) -
Relative P/E vs. SPX -
Earnings Per Share (ttm) -
Est. EPS -
Est. PEG Ratio -
Market Cap (M USD) 10.96
Shares Outstanding (M) 10.44
30 Day Average Volume 37
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement -
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for OPLI

No data available

Company Profile & Key Executives for OPLI

OphthaliX Inc. is an advanced clinical-stage biopharmaceutical company focused on drug development for the treatment of ophthalmic diseases. The Company's drug candidate is currently developed for ophthalmic indications including Dry Eye Syndrome(Phase3), Glaucoma (Phase 2) and Uveitis as well as or the treatment of autoimmune inflammatory diseases.

Pnina FishmanChairmanBarak SingerChief Executive Officer
Itay WeinsteinChief Financial OfficerRonen KantorSecretary
More Company Profile & Key Executives for OPLI

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil